Quarterly ResultAug 13, 2026, 03:56 PM
EXOZYMES Q2 Net Loss $(2.88)M; Raises $5.86M in Offerings
AI Summary
EXOZYMES INC. reported a net loss of $(2.88) million for the three months ended June 30, 2026, and $(5.25) million for the six months ended June 30, 2026, compared to $(2.36) million and $(4.22) million for the respective periods in 2025. The company disclosed substantial doubt about its ability to continue as a going concern due to anticipated funding shortfalls and its pre-revenue status. To address this, EXOZYMES completed an underwritten public offering and a concurrent registered direct offering in June 2026, generating net proceeds of $5.86 million from the issuance of common stock and warrants.
Key Highlights
- Net loss for Q2 2026 was $(2.88) million, up from $(2.36) million in Q2 2025.
- Net loss for H1 2026 was $(5.25) million, up from $(4.22) million in H1 2025.
- Cash and cash equivalents increased to $5.65 million at June 30, 2026, from $3.04 million at December 31, 2025.
- Total assets grew to $7.98 million at June 30, 2026, from $5.97 million at December 31, 2025.
- Net cash used in operating activities for H1 2026 was $(3.16) million, compared to $(2.67) million in H1 2025.
- Net proceeds from common stock and warrant offerings in June 2026 totaled $5.86 million.
- Accumulated deficit reached $(26.35) million at June 30, 2026.
- Research and development costs for H1 2026 increased to $2.56 million from $1.38 million in H1 2025.
Price Impact
More from EXOZ